Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
13/05/2025
Barclays: Maintains rating on Victory Capital Holdings (VCTR.US) at Hold, adjusting from Hold to Hold, with a target price adjusted from $59.00 to $62.00.
Latest
now
Has the progress been made in the "production reduction and price support" in the silicon material sector? Industry insiders: Leading silicon material enterprises have basically reached a consensus.
3 m ago
Spring sowing enters peak period, spring sown grains in Northeast China have reached nearly 30%.
4 m ago
Midea Wandon and Brazil's VMI Group reach significant cooperation agreement.
5 m ago
Manus responds to open registration: overseas users have been removed from the waiting list, domestic products have not yet been released.
8 m ago
According to CCTV news, on the local time of the 12th, President Trump of the United States signed an executive order requiring pharmaceutical companies to lower the pricing of prescription drugs in the United States to be aligned with other developed countries. Trump claimed that drug prices should decrease by at least 59% and in some cases the reduction should reach 80% to 90%. Analysis suggests that the excessively high drug prices in the United States are due to structural reasons. If European Union companies refuse to adjust drug prices, US tariff measures may lead to trade disputes and even exacerbate drug shortages.
See all latest